NCT01586052

Erythropoietin Therapy for Children With Cerebral Palsy: Phase 1

A Phase 1 Clinical Research of Erythropoietin Therapy for Children With Cerebral Palsy: Safety and Efficacy

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 11 (actual)
• Sponsor: MinYoung Kim, M.D. · Academic / Other
• Sex: All
• Age: 6 Months – 3 Years
• Healthy volunteers: Not accepted

Summary

This purpose of this phase 1 study is to investigate the safety and efficacy of erythropoetin for children with cerebral palsy.

Detailed description

Cerebral palsy is a disorder of movement and posture resulted from a nonprogressive lesion or injury of the immature brain. It is a leading cause of childhood onset disability. Many experimental animal studies have revealed that erythropoietin is useful to repair neurological injury in brain. The main mechanism of erythropoietin is supposed as follows; neuroprotection effect, angiogenesis, and anti-inflammation. On the basis of many experimental studies, erythropoietin is suggested as a potential therapy for cerebral palsy.

Conditions

• Cerebral Palsy

Interventions

Type	Name	Description
DRUG	Erythropoietin	250 IU/kg, Twice a week for 4 weeks

Timeline

• Start date: 2012-06-01
• Primary completion: 2013-10-01
• Completion: 2013-10-01
• First posted: 2012-04-26
• Last updated: 2014-04-08

Locations

1 site across 1 country: South Korea